Elevated endothelial microparticle—monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-β1b on release of endothelial microparticles,formation and transendothelial migration of monocyte-endothelial microparticle complexes

Abstract

Monocyte migration through the disrupted cerebral endothelial cell (EC) junctions plays an essential role in formation of multiple sclerosis (MS) demyelinating lesions. During pathogenesis of MS, activated ECs release endothelial microparticles (EMP), which possibly facilitate transendothelial migration (TEMIG) of monocytes. To assess functional roles of EMP in MS, specifically, their (i) interaction with monocytes, (ii) effect on monocyte TEMIG in an in vitro model of the brain microvascular endothelial cells (BMVEC), (iii) phenotypic profiles of EMP elicited by MS plasma and (iv) the effects of IFN-b1b on release of EMP and on TEMIG of monocytes (mono) and monocytes:EMP complexes (mono:EMP) through the BMVEC. The effect of IFN-b1b on the release of EMP and the TEMIG of mono and mono:EMP was assessed by preincubating BMVEC cultures of IFN-b1b prior to addition of plasma. Three EMP phenotypes, CD54, CD62E and CD31 were assayed. Plasma specimens from 20 patients with relapsing—remitting MS (11 in exacerbation, MS-E, and 9 in remission, ME-R) and 10 healthy controls were studied. Incubation of BMVEC with MS-E plasma yielded elevated levels of EMP_CD54, EMP_62E and EMP_CD31 relative to MS-R and control plasmas. MS-E but not MS-R or control plasma also augmented TEMIG of monocytes, respectively. Mono:EMP complexes further augmented TEMIG relative to mono alone, but only in the presence of MS-E plasma; there was no significant effect with MS-R or control plasmas. The presence of IFN-b1b inhibited TEMIG of mono and mono:EMP by 20% and 30%, respectively. MS-E but not MS-R plasma elicited release of activation-derived EMP and enhanced TEMIG of mono and mono:EMP. IFN-b1b inhibited TEMIG and release of EMP, suggesting a role of EMP and a novel therapeutic mechanism for IFN-β1b in MS.

Keywords

endothelial microparticle exacerbation interferon-β1b monocyte multiple sclerosis remission

Get full access to this article

View all access options for this article.

References

Noseworthy JH , Lucchinetti C , Rodriguez M , Weinshenker BG. Multiple sclerosis . N Engl J Med 2000; 343: 938-952 .

Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system . Cell 1996; 85: 299-302 .

Brosnan CF , Raine CS. Mechanisms of immune injury in multiple sclerosis . Brain Pathol 1996; 6: 243-257 .

Prat A , Biernacki K , Lavoie JF , Poireir J , Duquette P , Antel JP. Migration of multiple sclerosis lymphocytes through brain endothelium . Arch Neurol 2002; 59: 391-397 .

Hartung HP , Reiners K , Archelos JJ , Michels M , Seeldrayers P , Heidenreich F et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging . Ann Neurol 1995; 38: 186-193 .

Leppert D , Lindberg RL , Kappos L , Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis . Brain Res Brain Res Rev 2001; 36: 249-257 .

The IFNβ Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNβ Multiple Sclerosis Study Group . Neurology 1993; 43: 655-661 .

Uhm JH , Dooley NP , Stuve O , Francis GS , Duquette P , Antel JP et al. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy . Ann Neurol 1999; 46: 319-324 .

Corsini E , Gelati M , Dufour A , Ciusani E , La Mantia L , Massa G et al. Reduction of transendothelial migration of mononuclear cells in interferon-beta1b-treated multiple sclerosis patients . Ann Neurol 1999; 46: 435-435 .

10.

Losy J , Niezgoda A , Wender M. Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions . J Neuroimmunol 1999; 99: 169-172 .

11.

Minagar A , Jy W , Jimenez JJ , Sheremata WA , Mauro LM , Mao WW et al. Elevated plasma endothelial microparticles in multiple sclerosis . Neurology 2001; 56: 1319-1324 .

12.

Combes V , Simon AC , Grau GE , Arnoux D , Camoin L , Sabatier F et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant . J Clin Invest 1999; 104: 93-102 .

13.

Jimenez JJ , Jy W , Mauro LM , Soderland C , Horstman LL , Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis . Thromb Res 2003; 109: 175-180 .

14.

Sabatier F , Roux V , Anfosso F , Camoin L , Sampol J , Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity . Blood 2002; 99: 3962-3970 .

15.

Jy W , Minagar A , Jimenez JJ , Sheremata WA , Mauro LM , Horstman LL et al. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis . Front Biosci 2004; 9: 3137-3144 .

16.

Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

17.

Jimenez JJ , Jy W , Mauro LM , Horstman LL , Ahn YS. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease . Br J Haematol 2001; 112: 81-90 .

18.

Kermode AG , Thompson AJ , Tofts P , MacManus DG , Kendall BE , Kingsley DP et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications . Brain 1990; 113: 1477-1489 .

19.

Minagar A , Ostanin D , Long AC , Jennings M , Kelley RE , Sasaki M et al. Serum from patients with multiple sclerosis down-regulates occludin and VE-cadherin expression in cultured endothelial cells . Mult Scler 2003; 9: 235-238 .

20.

Minagar A , Long A , Ma T , Jackson TH , Kelley RE , Ostanin DV et al. Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier . Endothelium 2003; 10: 299-307 .

21.

Jy W , Jimenez JJ , Minagar A , Mauro L , Horstmann LL , Bidot CJ et al. Endothelial microparticles (EMP) enhance adhesion and transmigration of monocytes: EMP-monocyte conjugates as a marker of disease activity in multiple sclerosis (MS) . Blood 2002; 100: 460a-460a .

22.

Jy W , Jimenez JJ , Mauro L , Horstmann LL , Bernal-Mizrachi LL , Minagar A et al. Interaction of endothelial microparticles (EMP) with leukocytes: potential roles of EMP in thrombosis and inflammation . Blood 2001; 98: 226a-226a .

23.

Horstman LL , Jy W , Jimenez JJ , Ahn YS. Endothelial micro-particles as markers of endothelial dysfunction . Front Biosci 2004; 9: 1118-1135 .

24.

Stone LA , Frank JA , Albert PS , Bash C , Smith ME , Maloni H et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis . Ann Neurol 1995; 37: 611-619 .

25.

Calabresi PA , Tranquill LR , Dambrosia JM , Stone LA , Maloni H , Bash CN et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b . Ann Neurol 1997; 41: 669-674 .

26.

Dhib-Jalbut S , Jiang H , Williams GJ. The effect of interferon beta-1b on lymphocyte-endothelial cell adhesion . J Neuroimmunol 1996; 71: 215-222 .

27.

Floris S , Ruuls SR , Wierinckx A , van der Pol SM , Dopp E , van der Meide PH et al. Interferon-beta directly influences monocyte infiltration into the central nervous system . J Neuroimmunol 2002; 127: 69-79 .

28.

Corsini E , Gelati M , Dufour A , Massa G , Nespolo A , Ciusani E et al. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study . J Neuroimmunol 1997; 79: 76-83 .

29.

Sorensen TL , Roed H , Sellebjerg F. Chemokine receptor expression on B cells and effect of interferon-beta in multiple sclerosis . J Neuroimmunol 2002; 122: 125-131 .

30.

Iarlori C , Reale M , De Luca G , Di Iorio A , Feliciani C , Tulli A et al. Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis . J Neuroimmunol 2002; 123: 170-179 .

31.

Zang YC , Halder JB , Samanta AK , Samanta AK , Hong J , Rivera VM , Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta . J Neuroimmunol 2001; 112: 174-180 .

32.

Waubant E , Goodkin D , Bostrom A , Bacchetti P , Hietpas J , Lindberg R et al IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS . Neurology 2003; 60: 52-57 .

33.

Romanic AM , White RF , Arleth AJ , Ohlstein EH , Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size . Stroke 1998; 29: 1020-1030 .

34.

Stuve O , Chabot S , Jung SS , Williams G , Yong VW. Chemokine-enhanced migration of human peripheral blood mono-nuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9 . J Neuroimmunol 1997; 80: 38-46 .

35.

Jy W , Delgado S , Minagar A , Ahn Y , Sheremata W. Interferon-b1a reduces plasma CD31+ endothelial microparticles in MS . Ann Neurol 2003; 54: S60-S60 .